Dr. Steve Nissen, Chairman of Cardiovascular Medicine, discusses the results the ODYSSEY trail looking at the PCSK9 inhibitor alirocumab in patients who had a prior acute coronary syndrome and were on maximum statin therapy. Dr. Nissen provides us insight into the results and take-away message.